Trials / Terminated
TerminatedNCT00909298
Left Ventricular Assist Device (LVAD) Specialized Centers of Clinically Orientated Research (SCCOR) Coagulation - Acute Intrinsic Pathway Antagonist (IPA)
A Randomized Clinical Trial of Intrinsic Pathway Antagonists in Patients Undergoing Implantation of Left Ventricular Assist Devices
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- vTv Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if post-operative administration of intrinsic pathway antagonist (TTP889) in patients on Left Ventricular Assist Device (LVAD) support will result in a 50% reduction of thrombin generation markers at 28 days compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TTP889 | 300 mg |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2010-06-01
- First posted
- 2009-05-28
- Last updated
- 2011-06-27
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00909298. Inclusion in this directory is not an endorsement.